|
||
BRIEF DEFINITIVE REPORT |
CORRESPONDENCE Warren S. Pear: wpear{at}mail.med.upenn.edu
|
|
|---|
Notch signaling regulates multiple cell fate decisions in multicellular organisms. There are four mammalian Notch receptors (Notch1-4) whose signals converge in a common pathway. Upon binding to Jagged or Delta-like (Dll) ligands on an adjacent cell, two sequential proteolytic events release the intracellular domain of Notch (ICN) allowing its translocation to the nucleus where ICN converts the helix-loop-helix transcription factor CSL/RBP-J (for CBF1/RBP-Jk in mammals, Suppressor of Hairless in Drosophila melanogaster, Lag-1 in Caenorhabditis elegans) from a transcriptional repressor to a transcriptional activator. In the nucleus, Mastermind-like (MAML) proteins (1, 2) bind the ICNCSL/RBP-J complex and act as scaffolds to recruit coactivators, such as p300 (3). MAML is required for CSL/RBP-Jdependent Notch signaling, and inhibiting the ability of MAML proteins to recruit coactivators blocks transcriptional activation by Notch (4, 5).
Notch plays many roles in hematopoiesis and lymphopoiesis (6). Notch1 is required for T lineage commitment from multipotent hematopoietic progenitors (7, 8). Subsequently, Notch is required for efficient transit through the ß-selection checkpoint (9-11) and may also regulate 
T cell development (10, 12). Recent data propose multiple functions for Notch in peripheral T cells that include activation (13-15), tolerance induction (16), and helper T cell differentiation (10, 17, 18).
Naive CD4+ T cells differentiate into Th1 or Th2 cells when stimulated through their T cell antigen receptor. Th1 cells are characterized by expression of the transcription factor T-bet and produce IFN-
, which regulates cell-mediated protection against intracellular microbes such as Leishmania major (19). Th2 cells are characterized by expression of GATA-3 and the cytokines IL-4, IL-5, and IL-13, which mediate protection against parasitic helminths such as Trichuris muris (20).
Several studies implicate Notch signaling in CD4+ Th1 and Th2 cell differentiation. In vitro studies showed that expression of different Notch ligands on APCs have distinct effects on CD4+ T cell cytokine production. For example, Dll-1 induced IFN-
(17, 18), whereas Jagged1 induced IL-4 (18). Individual Notch receptors may also induce different responses, as ICN3 up-regulated T-bet and IFN-
expression (17), whereas ICN1 promoted expression of GATA-3 and IL-4 (18). The involvement of Notch in Th cell development is likely to be more complex than in vitro experiments suggest, as mice that conditionally inactivate Notch1 in their mature T cells have normal immune responses (21) and Dll ligands suppress IFN-
in some circumstances (16). Furthermore, mature T cells that are incapable of Notch signaling as a result of CSL/RBP-J deletion are impaired in IL-4 but not IFN-
production in vitro (10, 18). In contrast, use of a
-secretase inhibitor, a pharmacological inhibitor of Notch signaling among other pathways, inhibited only Th1 cell differentiation (22). Thus, it has not yet been resolved whether Notch regulates Th1 cell differentiation, Th2 cell differentiation, or both.
To elucidate the role of Notch signaling in peripheral T cell function, we engineered mice to conditionally express a dominant negative MAML (DNMAML) protein that blocks recruitment of coactivators by MAML proteins, thereby preventing transcriptional activation by all four Notch receptors (4, 5). Although T cell development and activation were normal, IL-4 production was impaired. When challenged with pathogens in vivo, mice that express DNMAML developed an effective Th1 cell response against L. major, but were susceptible to T. muris infection. These data show that CSL/RBP-Jdependent Notch signaling has a specific role in promoting type 2 immunity.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
|
2%) and gradually increased through DN4 and intermediate single positive stages (Fig. 1 C, ISP). GFP expression was high by the double positive (DP) stage (
93%) and reached
99% in single positive (SP) thymocytes. In addition, T cell subsets were purified and further sorted on the basis of GFP. Deletion of the floxed cassette was demonstrated by PCR on genomic DNA from sorted T cell subsets, which correlated with GFP expression (Fig. 1 C). Together, these data show that CD4-cre driven expression of the DNMAML transgene occurred in CCD mice.
Normal T cell development in CCD mice
Thymic cellularity and absolute numbers within all T cell subsets were normal in CCD mice (Fig. 2 A). In addition, the percentages of CD4+ and CD8+ single positive T cells were similar in CC and CCD mice (Fig. 2 B) Likewise, absolute numbers (Fig. 2 C) and percentages of T cells were normal in the spleen (Fig. 2 D) and lymph nodes (not depicted). In the periphery, >98% of CD4+ or CD8+ T cells were GFP+, demonstrating that single positive T cells had not encountered any selective pressures upon transit from the thymus to the periphery (Fig. 2 E). Peripheral T cells from CCD mice were stained for activation markers such as CD69, CD25, CD62L, and CD44. No differences were observed in baseline expression (Fig. 2 F).
|
|
The percentage of IFN-
producing cells increased in neutral and Th2 cell conditions compared to CC controls (Fig. 3 C). However there was no change in the percentage of IFN-
producing cells in Th1 cell conditions. This was in contrast to the increase in IFN-
detected by ELISA in all conditions and suggests that there may be differences in secretion of IFN-
over time (Fig. 3 D). Production of IFN-
in Th2 cell conditions may have been caused by the strong restimulation conditions. Together, these studies demonstrated that whereas CD4+ Th1 cell differentiation was intact in CCD CD4+ T cells, Notch signaling was required for optimal Th2 cell differentiation and expression of IL-4. However, it is unclear whether Notch directly promotes Th2 cell differentiation. It is possible that the absence of Notch may lead to an uncontrolled Th1 cell response that inhibits Th2 cell differentiation.
CCD mice fail to mount a Th2 cell response against T. muris
To investigate the in vivo requirement for Notch in response to an infection that normally elicits a protective Th2 cell response, CCD mice were infected with T. muris, a helminth pathogen of the murine gastrointestinal tract. Immunity is dependent on CD4+ Th2 cells that secrete IL-4 and IL-13. Genetically resistant B6 mice generate a Th2 cytokine response, which promotes goblet cell responses and control of infection by
21 d after infection (25). As expected, mesenteric lymph node cells isolated from T. murisinfected CC littermate controls exhibited robust parasite-specific IL-4, -5, and -13 responses (Fig. 4 A). In contrast, T. murisinfected CCD mice displayed decreased IL-4, -5, and -13 production, whereas IFN-
production was normal compared with CC mice (Fig. 4 A). Consistent with a defect in the expression of Th2 cytokines, infected CCD mice showed decreased levels of T. murisspecific serum IgG1 but IgG2a was increased (Fig. 4 B). Furthermore, total serum IgE, another hallmark of type 2 inflammation, was dramatically lower in infected CCD mice compared with infected CC mice. Histology of the gut revealed that although infected CC mice had pronounced Th2 cytokine-dependent goblet cell and mucin responses, there was an absence of goblet cell responses in infected CCD mice at day 21 after infection (Fig. 4 E). Whereas CC mice had a low worm burden at day 21, CCD mice exhibited high worm burdens, which is indicative of a persistent infection (Fig. 4 D). The level of infection in CCD mice was equivalent to that of immunodeficient RAG2/ mice, reflecting the severely impaired immune response in CCD mice. Furthermore, infection persisted in CCD mice at day 32 after inoculation (Fig. 4 F). Together, these results show that Notch signaling is required for optimal Th2 cytokine responses and resistance to helminth infection.
|
(Fig. 5 B). L. majorinfected CCD mice produced undetectable levels of IL-4 compared with low, but detectable, levels of IL-4 in PLN cultures isolated from infected CC mice (Fig. 5 C). Thus, in the absence of Notch signaling Th1-mediated immunity is preserved.
|
The failure to develop a sufficient Th2 cell response in CCD mice shows that optimal Th2 cell immunity is dependent on nuclear Notch signaling through CSL/RBP-J. Potential molecular targets of Notch signaling in Th2 cell differentiation include GATA-3 and IL-4. Both contain conserved CSL/RBP-J binding sites in important regulatory regions and the IL-4 regulatory region responded to Notch signals in vitro (18). Alternatively, Notch may promote Th2 cell differentiation by suppressing Th1 cell differentiation.
The normal Th1 cell response in CCD mice is strong evidence that Th1 cell differentiation does not require Notch signaling through the ICNMAMLCSL/RBP-J transcriptional activation complex. This is difficult to reconcile with overexpression data showing that ICN potentiates IFN-
production and can bind to the T-bet promoter (17, 22). Our data do not rule out effects of Notch signaling that are independent of CSL/RBP-J or MAML (26), however, this pathway is poorly understood.
Although our results do not exclude distinct roles for Notch ligands and receptors in Th1 and Th2 cell differentiation, they provide a foundation for determining the precise molecular pathways by which Notch controls helper T cell differentiation. Furthermore, our data suggest that Notch signaling is a potential therapeutic target in diseases characterized by pathologic Th2 cytokine responses, such as asthma, autoimmunity, and forms of inflammatory bowel disease.
| MATERIALS AND METHODS |
|---|
|
|
|---|
1.2 kb (27). PCR amplification was performed as follows: 93°C for 1.5 min, and then 40 cycles of 93°C for 30 s, 57°C for 30 s, followed by 65°C for 3 min. Next, 23 appropriately targeted clones were verified by Southern blot analysis using EcoRV digestion and hybridized with a probe recognizing the ROSA26 genomic sequences but not the targeting vector intended for homologous recombination. An 11-kb fragment from the wild-type allele and a new 3.8-kb fragment from the targeted allele were expected. Subsequently, the targeted embryonic stem cell clones were microinjected into C57BL/6 (B6) blastocysts by either the Abramson Family Cancer Research Institute Transgenic Mouse Core or the University of Pennsylvania Molecular Cardiology Research Center Transgenic Core. Chimeric males were bred with B6 females and heterozygous offspring were screened by PCR and Southern blot of tail DNA. These mice were designated as DNMAMLf/+. To express DNMAML1-GFP in mature T cells, DNMAML1f/+ mice were crossed with CD4-Cre transgenic mice (Taconic Farms). Mice expressing one allele of DNMAML1 were designated as CCD, whereas mice expressing only the CD4-Cre transgene were designated as CC. Mice were backcrossed onto the B6 background for at least five generations. CCD mice were compared with littermate CC controls in all experiments. B6 and RAG2/ mice were obtained from Taconic Farms. Experiments were performed according to guidelines from the National Institutes of Health and with an approved protocol from the University of Pennsylvania Animal Care and Use Committee.
In vitro T cell differentiation.
CD4+CD25 T cells from CC or CCD mice were sorted and cultured in IMDM (Life Technologies) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 50 µM 2-mercaptoethanol. T cells were stimulated with irradiated APCs and 0.1 µg/ml anti-CD3, 0.5 µg/ml anti-CD28, and 10 U/ml of recombinant human IL-2. No additional antibodies or cytokines were added to nonpolarizing conditions. 10 µg/ml antiIL-4 and 5 ng/ml of recombinant mIL-12 (PeproTech) was added in Th1 cell conditions. 10 µg/ml antiIL-12 and 20 ng/ml of recombinant mIL-4 (Peprotech) was added in Th2 cell conditions. Cells were differentiated for 7 d and restimulated with 50 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h. During the last 2 h, 2 µg/ml Brefeldin A (Sigma-Aldrich) was added. Cells were washed, fixed in 4% paraformaldehyde and permeabilized in 2% saponin (Sigma-Aldrich). For ELISAs, equal numbers of viable CD4+ T cells were plated in triplicate and restimulated with 2.5 µg/ml of plate-bound anti-CD3. After 24 h, supernatants were collected and standard sandwich ELISA protocols were used. CFSE labeling was performed as previously described (14).
Flow cytometry, cell sorting, and antibodies.
After incubating with 2.4G2 hybridoma supernatant to block Fc receptors, cell suspensions were stained with primary antibodies and washed in 2% FBS and 0.01% NaN3. Data were acquired on FACSCalibur (Becton Dickinson) and analyzed using FlowJo software (Tree Star). CD4+ and CD4+GFP+ T cells were sorted on a MoFlo cytometer (DakoCytomation). All antibodies were obtained from BD PharMingen except antiIL-13 antibodies, which were from R&D Systems.
T. muris infection and antigen.
T. muris was maintained in genetically susceptible or immunocompromised mice. Between days 35 and 42 after infection, adult worms were isolated and cultured in RPMI 1640 (Life Technologies) containing 500 U/ml penicillin and 500 µg/ml streptomycin for 24 h. T. muris excretorysecretory antigen was isolated at 4 and 24 h, dialyzed, and sterile filtered, and protein concentrations were determined by Bradford assay. Antigen preparations were then used in lymphocyte restimulations (50 µg/ml). Deposited eggs were collected after 24 h of culture, washed three times in sterile water, incubated at room temperature for 6 wk and stored at 4°C. Mice were infected on day 0 with 150200 embryonated eggs, and parasite burdens were assessed on day 21 after infection. Mesenteric LN (MLN) cell suspensions were prepared and resuspended in IMDM supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 50 µM 2-mercaptoethanol. Cells were plated at 4 x 106 cells/well and cultured alone or in the presence of T. muris Ag for 72 h. Levels of IL-4, -5, and -13 and IFN-
were assayed by sandwich ELISA. For histology, segments of mid-cecum were removed, washed in sterile PBS, and fixed for 24 h in paraformaldehyde. Tissues were processed and paraffin embedded using standard histological techniques. For detection of intestinal goblet cells, 5-µm sections were cut and stained with hematoxylin and eosin or Alcian blue periodic acid Schiff. Analysis of parasite-specific IgG1 and IgG2a production was performed by antigen capture ELISA using biotinylated rat antimouse IgG1 and IgG2a (BD Biosciences). Total serum levels of IgE were determined by ELISA (BD Biosciences).
L. major infection and antigen.
L. major parasites (MHOM/IL/80/Friedlin) were grown in Grace's insect culture medium (Life Technologies) supplemented with 20% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin. Soluble Leishmania Ag (SLA) was prepared as previously described (28). Mice were injected in the hind left footpad with 5 x 106 stationary phase promastigote parasites. Footpad swelling was measured weekly using digital calipers (Mitutoyo), and lesion size was determined by subtracting the size of the uninfected contralateral footpad from the size of the infected footpad. PLN cells from infected mice were restimulated with SLA for 4 d. Intracellular staining and ELISA were performed as described above.
Online supplemental material.
Fig. S1 shows that DNMAML can inhibit Notch3 and Notch4 driven T cell development and is available at http://www.jem.org/cgi/content/full/jem20050923/DC1.
| Acknowledgments |
|---|
This work was supported by the grants from the National Institutes of Health to D. Artis (AI61570) and W.S. Pear. Individual support was provided by the Hematology Clinical Research training program (T32HL007439-27) to L. Tu, a predoctoral training grant from the Cancer Research Institute to T.C. Fang, a fellow award from the Damon Runyun Cancer Research Foundation (DRG-102-05) to I. Maillard, and the Crohn's and Colitis Foundation of America's William and Shelby Model Family Foundation Research Award to D. Artis.
The authors have no conflicting financial interests.
Submitted: 9 May 2005
Accepted: 7 September 2005
| References |
|---|
|
|
|---|
1 Wu, L., J.C. Aster, S.C. Blacklow, R. Lake, S. Artavanis-Tsakonas, and J.D. Griffin. 2000. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat. Genet. 26:484489.[CrossRef][Medline]
2 Nam, Y., A.P. Weng, J.C. Aster, and S.C. Blacklow. 2003. Structural requirements for assembly of the CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation complex. J. Biol. Chem. 278:2123221239.
3 Wallberg, A.E., K. Pedersen, U. Lendahl, and R.G. Roeder. 2002. p300 and PCAF act cooperatively to mediate transcriptional activation from chromatin templates by notch intracellular domains in vitro. Mol. Cell. Biol. 22:78127819.
4 Weng, A.P., Y. Nam, M.S. Wolfe, W.S. Pear, J.D. Griffin, S.C. Blacklow, and J.C. Aster. 2003. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol. Cell. Biol. 23:655664.
5 Maillard, I., A.P. Weng, A.C. Carpenter, C.G. Rodriguez, H. Sai, L. Xu, D. Allman, J.C. Aster, and W.S. Pear. 2004. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood. 104:16961702.
6 Maillard, I., T. Fang, and W.S. Pear. 2005. Regulation of lymphoid development, differentiation, and function by the Notch pathway. Annu. Rev. Immunol. 23:945974.[CrossRef][Medline]
7 Radtke, F., A. Wilson, G. Stark, M. Bauer, J. van Meerwijk, H.R. MacDonald, and M. Aguet. 1999. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity. 10:547558.[CrossRef][Medline]
8 Pui, J.C., D. Allman, L. Xu, S. DeRocco, F.G. Karnell, S. Bakkour, J.Y. Lee, T. Kadesch, R.R. Hardy, J.C. Aster, and W.S. Pear. 1999. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 11:299308.[CrossRef][Medline]
9 Wolfer, A., A. Wilson, M. Nemir, H.R. MacDonald, and F. Radtke. 2002. Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta lineage thymocytes. Immunity. 16:869879.[CrossRef][Medline]
10 Tanigaki, K., M. Tsuji, N. Yamamoto, H. Han, J. Tsukada, H. Inoue, M. Kubo, and T. Honjo. 2004. Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity. 20:611622.[CrossRef][Medline]
11 Ciofani, M., T.M. Schmitt, A. Ciofani, A.M. Michie, N. Cuburu, A. Aublin, J.L. Maryanski, and J.C. Zuniga-Pflucker. 2004. Obligatory role for cooperative signaling by pre-TCR and Notch during thymocyte differentiation. J. Immunol. 172:52305239.
12 Washburn, T., E. Schweighoffer, T. Gridley, D. Chang, B.J. Fowlkes, D. Cado, and E. Robey. 1997. Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell. 88:833843.[CrossRef][Medline]
13 Palaga, T., L. Miele, T.E. Golde, and B.A. Osborne. 2003. TCR-mediated notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. J. Immunol. 171:30193024.
14 Adler, S.H., E. Chiffoleau, L. Xu, N.M. Dalton, J.M. Burg, A.D. Wells, M.S. Wolfe, L.A. Turka, and W.S. Pear. 2003. Notch signaling augments T cell responsiveness by enhancing CD25 expression. J. Immunol. 171:28962903.
15 Eagar, T.N., Q. Tang, M. Wolfe, Y. He, W.S. Pear, and J.A. Bluestone. 2004. Notch 1 signaling regulates peripheral T cell activation. Immunity. 20:407415.[CrossRef][Medline]
16 Wong, K.K., M.J. Carpenter, L.L. Young, S.J. Walker, G. McKenzie, A.J. Rust, G. Ward, L. Packwood, K. Wahl, L. Delriviere, et al. 2003. Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8+ cell-dependent mechanism. J. Clin. Invest. 112:17411750.[CrossRef][Medline]
17 Maekawa, Y., S. Tsukumo, S. Chiba, H. Hirai, Y. Hayashi, H. Okada, K. Kishihara, and K. Yasutomo. 2003. Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity. 19:549559.[CrossRef][Medline]
18 Amsen, D., J.M. Blander, G.R. Lee, K. Tanigaki, T. Honjo, and R.A. Flavell. 2004. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell. 117:515526.[CrossRef][Medline]
19 Murphy, K.M., and S.L. Reiner. 2002. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2:933944.[CrossRef][Medline]
20 Mowen, K.A., and L.H. Glimcher. 2004. Signaling pathways in Th2 development. Immunol. Rev. 202:203222.[CrossRef][Medline]
21 Tacchini-Cottier, F., C. Allenbach, L.A. Otten, and F. Radtke. 2004. Notch1 expression on T cells is not required for CD4+ T helper differentiation. Eur. J. Immunol. 34:15881596.[CrossRef][Medline]
22 Minter, L.M., D.M. Turley, P. Das, H.M. Shin, I. Joshi, R.G. Lawlor, O.H. Cho, T. Palaga, S. Gottipati, J.C. Telfer, et al. 2005. Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat. Immunol. 6:680688.[CrossRef][Medline]
23 Srinivas, S., T. Watanabe, C.S. Lin, C.M. William, Y. Tanabe, T.M. Jessell, and F. Costantini. 2001. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 10.1186/1471-213X-1-4.[CrossRef][Medline]
24 Maillard, I., A.P. Weng, A.C. Carpenter, C.G. Rodriguez, H. Sai, L. Xu, D. Allman, J.C. Aster, and W.S. Pear. 2004. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood. 106:16961702.
25 Artis, D., A. Villarino, M. Silverman, W. He, E.M. Thornton, S. Mu, S. Summer, T.M. Covey, E. Huang, H. Yoshida, et al. 2004. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 173:56265634.
26 Martinez Arias, A., V. Zecchini, and K. Brennan. 2002. CSL-independent Notch signalling: a checkpoint in cell fate decisions during development? Curr. Opin. Genet. Dev. 12:524533.[CrossRef][Medline]
27 Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21:7071.[CrossRef][Medline]
28 Scott, P., E. Pearce, P. Natovitz, and A. Sher. 1987. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. J. Immunol. 139:31183125.[Abstract]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|